Back
Corporate News
Corona Remedies reports Rs 422.4 crore revenue, 21.9% YoY increase, and opens EU-GMP facility
31-Jul-2026, 06:22
CORONA Remedies Limited announced its unaudited financial results for the first quarter of fiscal year 2027, reporting revenue of Rs 422.4 crore, a 21.9% year-over-year increase, and profit after tax of Rs 60.1 crore, a 30.1% year-over-year increase. The company, a leading India-focused branded pharmaceutical company, also inaugurated a European Union Good Manufacturing Practice (EU-GMP) approved Female Hormone Manufacturing Facility in Ahmedabad and initiated the integration of the acquired brand, Wokadine.
CORONA Remedies Limited announced its unaudited financial results for the first quarter of fiscal year 2027, reporting revenue of Rs 422.4 crore, a 21.9% year-over-year increase, and profit after tax of Rs 60.1 crore, a 30.1% year-over-year increase. The company, a leading India-focused branded pharmaceutical company, also inaugurated a European Union Good Manufacturing Practice (EU-GMP) approved Female Hormone Manufacturing Facility in Ahmedabad and initiated the integration of the acquired brand, Wokadine.